Unknown

Dataset Information

0

Discovery of Potent and Selective A2A Antagonists with Efficacy in Animal Models of Parkinson's Disease and Depression.

ABSTRACT: Adenosine A2A receptor (A2AAdoR) antagonism is a nondopaminergic approach to Parkinson's disease treatment that is under development. Earlier we had reported the therapeutic potential of 7-methoxy-4-morpholino-benzothiazole derivatives as A2AAdoR antagonists. We herein described a novel series of [1,2,4]triazolo[5,1-f]purin-2-one derivatives that displays functional antagonism of the A2A receptor with a high degree of selectivity over A1, A2B, and A3 receptors. Compounds from this new scaffold resulted in the discovery of highly potent, selective, stable, and moderate brain penetrating compound 33. Compound 33 endowed with satisfactory in vitro and in vivo pharmacokinetics properties. Compound 33 demonstrated robust oral efficacies in two commonly used models of Parkinson's disease (haloperidol-induced catalepsy and 6-OHDA lesioned rat models) and depression (TST and FST mice models).

SUBMITTER: Basu S 

PROVIDER: S-EPMC5554908 | biostudies-literature | 2017 Aug

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Adenosine A<sub>2A</sub> receptor (A<sub>2A</sub>AdoR) antagonism is a nondopaminergic approach to Parkinson's disease treatment that is under development. Earlier we had reported the therapeutic potential of 7-methoxy-4-morpholino-benzothiazole derivatives as A<sub>2A</sub>AdoR antagonists. We herein described a novel series of [1,2,4]triazolo[5,1-<i>f</i>]purin-2-one derivatives that displays functional antagonism of the A<sub>2A</sub> receptor with a high degree of selectivity over A<sub>1</s  ...[more]

Similar Datasets

Unknown The discovery of a selective and potent A2a agonist with extended lung retention.
| S-EPMC4492750 | biostudies-literature
Transcriptomics Structure-Based Discovery of Potent WD Repeat Domain 5 Inhibitors that Demonstrate Efficacy and Safety in Preclinical Animal Models
2022-10-01 | GSE203101 | GEO
Unknown Discovery of 3-substituted aminocyclopentanes as potent and orally bioavailable NR2B subtype-selective NMDA antagonists.
| S-EPMC3369735 | biostudies-literature
Unknown Behavioral animal models of depression.
| S-EPMC5552573 | biostudies-other
Unknown Investigation around the Oxadiazole Core in the Discovery of a New Chemotype of Potent and Selective FXR Antagonists.
| S-EPMC6466555 | biostudies-literature
Unknown Discovery of 3,4-Dihydropyrimidin-2(1H)-ones As a Novel Class of Potent and Selective A2B Adenosine Receptor Antagonists.
| S-EPMC4027370 | biostudies-literature
Unknown Discovery and Optimization of Highly Potent and Selective AT<sub>2</sub>R Antagonists to Relieve Peripheral Neuropathic Pain.
| S-EPMC8210434 | biostudies-literature
Unknown Synthesis and evaluation of 1,2,4-triazolo[1,5-c]pyrimidine derivatives as A2A receptor-selective antagonists.
| S-EPMC2946083 | biostudies-literature
Unknown Simple Tetrahydroisoquinolines Are Potent and Selective Kappa Opioid Receptor Antagonists.
| S-EPMC5512122 | biostudies-literature
Unknown Discovery of blood transcriptomic markers for depression in animal models and pilot validation in subjects with early-onset major depression.
| S-EPMC3337072 | biostudies-literature